Analyst Reco. Johnson & Johnson Buenos Aires S.E.

Equities

JNJ

ARDEUT110236

End-of-day quote Buenos Aires S.E. Other stock markets 18:00:00 2024-06-06 EDT			5-day change	1st Jan Change
12,876 ^ARS	+1.44%		+5.47%	+27.05%

06-08	Top law firms in US opioid lawsuits to get hundreds of millions in fees	RE
06-07	J&J-backed Rapport Therapeutics shares debut nearly 6% higher	RE

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating	06-06	MT
Guggenheim Adjusts Johnson & Johnson's Price Target to $160 From $167	05-01	MT
Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170	04-25	MT
Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	04-22	MT
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169	04-18	MT
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating	04-18	MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating	04-18	MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating	04-17	MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating	04-17	MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating	04-17	MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating	04-17	MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160	04-16	MT
Morgan Stanley Trims Price Target on Johnson & Johnson to $168 From $169, Keeps Equalweight Rating	04-09	MT
Johnson & Johnson Recommends Shareholders to Reject TRC Capital Investment's Mini-Tender Offer	04-05	MT
J&J recommends shareholders to reject 'mini-tender' offer by TRC Capital Investment	04-04	RE
Guggenheim Trims Price Target on Johnson & Johnson to $167 From $169, Maintains Neutral Rating	01-24	MT
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $170, Maintains Equalweight Rating	01-24	MT
The market awaits the BCE meeting and earnings reports	01-23
The start of a new bull market?	01-22
B. Riley Downgrades Ambrx Biopharma to Neutral From Buy on Heels of Announced Sale to Johnson & Johnson, Adjusts PT to $28 From $26	01-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm